Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia
Hematology/Oncology and Stem Cell Therapy · 2017-01 · 10 (1) · 1-7
DOI: 10.1016/j.hemonc.2016.08.005 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Hematology/Oncology and Stem Cell Therapy, 2017-01. Verfasst von Hossein Ayatollahi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective/background: Acute myeloid leukemia (AML) is defined as leukemic blast reproduction in bone marrow. Chromosomal abnormalities form different subgroups with joint clinical specifications and results. t(8;21)(q22;q22) and inv(16)(p13;q22) form core binding factor- AML (CBF-AML). c-kit mutation activation occurs in 12.8–46.1% of adults with CBF leukemia. These mutations occur in 20–25% of t(8;21) and 30% of inv(16) cases.
Methods
In this systematic review, we searched different databases, including PubMed, Scopus, and Embase. Selected articles were measured based on the inclusion criteria of this study and initially compared in terms of titles or abstracts. Finally, articles relevant to the subject of this review were retrieved in full text. Twenty-two articles matched the inclusion criteria and were selected for this review.
Results
In this study, c-kit mutations were associated with poor prognosis in AML patients with t(8;21) and inv(16). In addition, these mutations had better prognostic effects on AML patients with inv(16) compared with those with t(8;21).
Conclusion
According to the results of this study, c-kit mutations have intense, harmful effects on the relapse and white blood cell increase in CBF-AML adults. However, these mutations have no significant prognostic effects on patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Hematology and Blood Bank, Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: sheikhim75@gmail.com.
- Department of Midwifery, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
Zitieren
APA
Ayatollahi, H., Shajiei, A., Sadeghian, M. H., Sheikhi, M., Yazdandoust, E., Ghazanfarpour, M., Shams, S. F., & Shakeri, S. (2017). Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia. Hematology/Oncology and Stem Cell Therapy, 10(1), 1-7. https://doi.org/10.1016/j.hemonc.2016.08.005
Vancouver
Ayatollahi H, Shajiei A, Sadeghian MH, Sheikhi M, Yazdandoust E, Ghazanfarpour M, et al. Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia. Hematology/Oncology and Stem Cell Therapy. 2017;10(1):1-7. doi:10.1016/j.hemonc.2016.08.005
BibTeX
@article{Ayatollahi2017,
author = {Ayatollahi, Hossein and Shajiei, Arezoo and Sadeghian, Mohammad Hadi and Sheikhi, Maryam and Yazdandoust, Ehsan and Ghazanfarpour, Masumeh and Shams, Seyyede Fatemeh and Shakeri, Sepideh},
title = {Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia},
journal = {Hematology/Oncology and Stem Cell Therapy},
year = {2017},
volume = {10},
number = {1},
pages = {1--7},
doi = {10.1016/j.hemonc.2016.08.005}
}
EUVIMED